{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:39:33Z","timestamp":1791941973286,"version":"4.3.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-025-01432-3","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T14:22:54Z","timestamp":1758032574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rebound Effect Following the Discontinuation of Palopegteriparatide"],"prefix":"10.1007","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-3381","authenticated-orcid":false,"given":"Anda Mihaela","family":"Naciu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Sargentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-1906","authenticated-orcid":false,"given":"Elena","family":"Tsourdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-4926","authenticated-orcid":false,"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-0700","authenticated-orcid":false,"given":"Gaia","family":"Tabacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"1432_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/S41574-024-01075-8","author":"S Khan","year":"2025","unstructured":"Khan S, Khan AA (2025) Hypoparathyroidism: diagnosis, management and emerging therapies. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/S41574-024-01075-8","journal-title":"Nat Rev Endocrinol"},{"key":"1432_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/S11914-025-00905-6","author":"A Palermo","year":"2025","unstructured":"Palermo A, Naciu AM, Donovan YKT et al (2025) PTH substitution therapy for chronic hypoparathyroidism: PTH 1\u201384 and palopegteriparatide. Curr Osteoporos Rep. https:\/\/doi.org\/10.1007\/S11914-025-00905-6","journal-title":"Curr Osteoporos Rep"},{"key":"1432_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","volume":"1","author":"M Mannstadt","year":"2013","unstructured":"Mannstadt M, Clarke BL, Vokes T et al (2013) Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol 1:275\u2013283. https:\/\/doi.org\/10.1016\/S2213-8587(13)70106-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1432_CR4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01555","author":"A Palermo","year":"2018","unstructured":"Palermo A, Santonati A, Tabacco G et al (2018) PTH(1\u201334) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2017-01555","journal-title":"J Clin Endocrinol Metab"},{"key":"1432_CR5","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/JBMR.4016","volume":"35","author":"DB Karpf","year":"2020","unstructured":"Karpf DB, Pihl S, Mourya S et al (2020) A randomized double-blind placebo-controlled first-in-human phase 1 trial of TransCon PTH in healthy adults. J Bone Miner Res 35:1430\u20131440. https:\/\/doi.org\/10.1002\/JBMR.4016","journal-title":"J Bone Miner Res"},{"key":"1432_CR6","doi-asserted-by":"publisher","first-page":"E372","DOI":"10.1210\/CLINEM\/DGAB577","volume":"107","author":"AA Khan","year":"2022","unstructured":"Khan AA, Rejnmark L, Rubin M et al (2022) Path forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism. J Clin Endocrinol Metab 107:E372\u2013E385. https:\/\/doi.org\/10.1210\/CLINEM\/DGAB577","journal-title":"J Clin Endocrinol Metab"},{"key":"1432_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/JBMR.4726","volume":"38","author":"AA Khan","year":"2023","unstructured":"Khan AA, Rubin MR, Schwarz P et al (2023) Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 pathway trial. J Bone Miner Res 38:14\u201325. https:\/\/doi.org\/10.1002\/JBMR.4726","journal-title":"J Bone Miner Res"},{"key":"1432_CR8","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1007\/S12325-024-02843-8","volume":"41","author":"L Rejnmark","year":"2024","unstructured":"Rejnmark L, Gosmanova EO, Khan AA et al (2024) Palopegteriparatide treatment improves renal function in adults with chronic hypoparathyroidism: 1-year results from the phase 3 pathway trial. Adv Ther 41:2500\u20132518. https:\/\/doi.org\/10.1007\/S12325-024-02843-8","journal-title":"Adv Ther"},{"key":"1432_CR9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1210\/CLINEM\/DGAE693","volume":"110","author":"BL Clarke","year":"2025","unstructured":"Clarke BL, Khan AA, Rubin MR et al (2025) Efficacy and safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the phase 3 pathway trial. J Clin Endocrinol Metab 110:951\u2013960. https:\/\/doi.org\/10.1210\/CLINEM\/DGAE693","journal-title":"J Clin Endocrinol Metab"},{"key":"1432_CR10","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/JBMR.2555","volume":"30","author":"RI Gafni","year":"2015","unstructured":"Gafni RI, Guthrie LC, Kelly MH et al (2015) Transient increased calcium and calcitriol requirements after discontinuation of human synthetic parathyroid hormone 1\u201334 (hPTH 1\u201334) replacement therapy in hypoparathyroidism. J Bone Miner Res 30:2112\u20132118. https:\/\/doi.org\/10.1002\/JBMR.2555","journal-title":"J Bone Miner Res"},{"key":"1432_CR11","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1002\/jbmr.4716","volume":"37","author":"AA Khan","year":"2022","unstructured":"Khan AA, Guyatt G, Ali DS et al (2022) Management of hypoparathyroidism. J Bone Miner Res 37:2663\u20132677. https:\/\/doi.org\/10.1002\/jbmr.4716","journal-title":"J Bone Miner Res"},{"key":"1432_CR12","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1530\/EJE-21-1044","volume":"186","author":"J Bollerslev","year":"2022","unstructured":"Bollerslev J, Rejnmark L, Zahn A et al (2022) European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders. Eur J Endocrinol 186:R33\u2013R63. https:\/\/doi.org\/10.1530\/EJE-21-1044","journal-title":"Eur J Endocrinol"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01432-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-025-01432-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01432-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T13:21:42Z","timestamp":1766755302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-025-01432-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1432"],"URL":"https:\/\/doi.org\/10.1007\/s00223-025-01432-3","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AP served as a consultant for Ascendis, and he has received travel grant from Ascendis. A.M.N received travel grant from Ascendis. ET reports honoraria for lectures and consultancies from Ascendis. All the other authors state that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Patient signed the informed consent for data sharing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent statements"}}],"article-number":"121"}}